Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13276647 | 0.89 | PYGB (0.41) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL8073770 | 0.86 | PYGB (0.37) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL8071533 | 0.84 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL667997 | 0.84 | PYGB (0.37) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL1882532 | 0.84 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL25366499 | 0.83 | GAA (0.37) | PYGBPYGLPYGM | |
| SCHEMBL5551957 | 0.83 | GAA (0.37) | PYGBPYGLPYGM | |
| SCHEMBL9699515 | 0.83 | GAA (0.37) | PYGBPYGLPYGM | |
| SCHEMBL22409570 | 0.83 | GAA (0.37) | PYGBPYGLPYGM | |
| Water SCHEMBL21808164 | 0.83 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024246793-A1 | ACTIVE INGREDIENT COMPLEX AND METHOD OF MAKING THEREOF | HALEON US HOLDINGS LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4470528-A1 | ACTIVE INGREDIENT COMPLEX AND METHOD OF MAKING THEREOF | Haleon US Holdings LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119055788-A | Active ingredient complex and preparation method thereof | 葛兰素史克消费保健（美国）控股有限责任公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-103781472-B | Synthesis and use of propofol glycoside derivatives | 纽泰克制药有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9023813-B2 | Synthesis and use of glycoside derivatives of propofol | NuTek Pharma Ltd. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-103781472-A | Synthesis and use of propofol glycoside derivatives | NUTEK PHARMA LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103702670-A | Synthesis and use of glycoside pro-drug analogs | NUTEK PHARMA LTD | 2014-04-02 | — | — | CN | disclosed |
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-11-22 | — | — | US | disclosed |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | NuTek Pharma Ltd. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | GCG, CYP3A5, UGT1A6 | PYGB 132/4885PYGL 68/4885PYGM 168/4885 |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | CYP3A5, CYP3A4, UGT1A4 | PYGB 173/4885PYGL 144/4885PYGM 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.